Inhibikase Therapeutics, Inc. (IKT) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -65.44M USD | Operating Income (Loss) |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 38.24M USD | Research and Development Expense |
| Selling, general and administration | 27.42M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-65.44M | (m) | (m) | $38.24M | $27.42M | (m) |
| 2026-03-31 | $-55.22M | (m) | (m) | $30.12M | $25.68M | (m) |
| 2025-12-31 | $-51.97M | (m) | (m) | $29.79M | $23.56M | (m) |
| 2025-09-30 | $-51.13M | $0.00 | (m) | $30.63M | $22.52M | (m) |
| 2025-06-30 | $-44.19M | $0.00 | (m) | $27.17M | $18.54M | (m) |
| 2025-03-31 | $-38.40M | $0.00 | (m) | $24.97M | $14.60M | (m) |
| 2024-12-31 | $-28.59M | $0.00 | (m) | $17.21M | $11.38M | (m) |
| 2024-09-30 | $-20.06M | $1.00 | (m) | $13.02M | $7.04M | -2006393400.00% |
| 2024-06-30 | $-19.01M | $79.57K | (m) | $12.06M | $7.03M | -23885.05% |
| 2024-03-31 | $-20.16M | $195.98K | (m) | $13.52M | $6.84M | -10285.34% |
| 2023-12-31 | $-20.09M | $260.50K | (m) | $13.62M | $6.73M | -7711.98% |
| 2023-09-30 | $-20.02M | $324.07K | (m) | $13.67M | $6.68M | -6178.12% |
| 2023-06-30 | $-19.77M | $251.79K | (m) | $13.43M | $6.59M | -7850.03% |
| 2023-03-31 | $-18.20M | $141.93K | (m) | $11.87M | $6.47M | -12825.31% |
| 2022-12-31 | $-18.13M | $123.44K | (m) | $12.03M | $6.22M | -14686.17% |
| 2022-09-30 | $-18.84M | $61.82K | (m) | $12.37M | $6.53M | -30468.63% |
| 2022-06-30 | $-18.79M | $382.99K | (m) | $12.54M | $6.63M | -4906.98% |
| 2022-03-31 | $-16.78M | $1.74M | (m) | $11.94M | $6.58M | -964.75% |
| 2021-12-31 | $-14.77M | $3.10M | (m) | $11.36M | $6.51M | -476.23% |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-2.82M | $698.47K | (m) | $893.80K | $2.62M | -403.52% |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |